Live Breaking News & Updates on Immunos Therapeutics

Stay updated with breaking news from Immunos therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023

HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptorDesigned to target myeloid, NK and T cells and to be precisely directed to t. ....

United States , Marroquin Belaunzaran , Ludger Wess Ines Regina Buth , Schroder Adveq , Oncology Congress , Mission Biocapital , Company Contact , Zurich Area , Immunos Therapeutics , Osiris Marroquin Belaunzaran , Steve Coats , Samsara Biocapital , Lightspeed Venture Partners , Pfizer Ventures , Biomed Partners , Ludger Wess , Ines Regina Buth ,

ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002

Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress 2023 (Madrid, Spain)Dose ....

United States , Schroder Adveq , Christoph Renner , Ludger Wess Ines Regina Buth , Company Contact , Mission Biocapital , Zurich Area , Immunos Therapeutics , Samsara Biocapital , Lightspeed Venture Partners , Pfizer Ventures , Biomed Partners , Ludger Wess ,

ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ...

- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ....

United States , Schroder Adveq , Seanr Smith , Christoph Renner , Ludger Wess Ines Regina Buth , Merck Co Inc , Mission Biocapital , Merck Sharp Dohme , Zurich Area , Immunos Therapeutics , Chief Medical Officer , Chief Executive Officer , Merck Sharp , Samsara Biocapital , Lightspeed Venture Partners , Pfizer Ventures , Biomed Partners , Ludger Wess ,

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Santa Clara University , United States , Wharton School , University Of Texas , Ludger Wess Ines Regina Buth , Joseph Leveque , Seanr Smith , Eli Lilly , Joe Leveque , Bristol Myers Squibb , Los Angeles , Schroder Adveq , University Of California , Sinai Medical Center , Mission Biocapital , Company Contactimmunos Therapeutics Ag Wagistrasse , Merck Kga , Merck Kgaa , Onyx Pharmaceuticals , Wharton School Of The University Pennsylvania , University Of Texas School Medicine , Wall Street , Zurich Area , Immunos Therapeutics , Chief Medical Officer , Board Member ,

ImmunOs Therapeutics Announces Appointment of Joseph

- Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD,. ....

Santa Clara University , United States , Wharton School , University Of Texas , Ludger Wess Ines Regina Buth , Joseph Leveque , Seanr Smith , Eli Lilly , Joe Leveque , Bristol Myers Squibb , Los Angeles , Schroder Adveq , University Of California , Sinai Medical Center , Company Contact , Mission Biocapital , Merck Kga , Merck Kgaa , Onyx Pharmaceuticals , Wharton School Of The University Pennsylvania , University Of Texas School Medicine , Zurich Area , Immunos Therapeutics , Chief Medical Officer , Board Member , Executive Vice President ,